Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
Completed
- Conditions
- Chronic Myeloid Leukemia (CML)
- Registration Number
- NCT02363868
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 186
Inclusion Criteria
- Age >18 years
- International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) code for CML (205.1x)
- At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013
- Continuous eligibility for the 6 months pre- and post-index date (defined as the date of first fill for dasatinib or nilotinib)
Exclusion Criteria
- History of bone marrow or stem cell transplant as identified in the 6 month pre-period
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Healthcare costs Intent-to-treat (ITT) at 6 months Average (mean) costs for patients receiving dasatinib or nilotinib as first line therapy
- Secondary Outcome Measures
Name Time Method Healthcare costs by line of therapy Intent-to-treat (ITT) at 6 months Resource utilization by line of therapy Intent-to-treat (ITT) at 6 months Captured per number of hospitalizations, Emergency room (ER) visits, physician office visits, and medications / number of prescriptions
Trial Locations
- Locations (1)
Franklin Pharmaceutical Consulting, Llc
🇺🇸Clinton, South Carolina, United States
Franklin Pharmaceutical Consulting, Llc🇺🇸Clinton, South Carolina, United States